18013864. METHODS TO GLYCOENGINEER PROTEINS simplified abstract (THE JOHNS HOPKINS UNIVERSITY)

METHODS TO GLYCOENGINEER PROTEINS

Organization Name

THE JOHNS HOPKINS UNIVERSITY

Inventor(s)

Kevin J. Yarema of Woodstock MD (US)

Christian Agatemor of Baltimore MD (US)

Christopher T. Saeui of Rockville MD (US)

Matthew Buettner of Baltimore MD (US)

Jamie Spangler of Baltimore MD (US)

Seth Ludwig of Baltimore MD (US)

Riddhima Dennar Chitre of Baltimore MD (US)

Kris Dammem-brower of Baltimore MD (US)

Zachary Bernstein of Baltimore MD (US)

METHODS TO GLYCOENGINEER PROTEINS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18013864 titled 'METHODS TO GLYCOENGINEER PROTEINS

Simplified Explanation: The patent application discusses compositions for producing glycoengineered proteins, such as antibodies, using host cells that lack enzymes affecting sialic acid metabolic flux.

Key Features and Innovation:

• Host cells without enzymes modulating sialic acid metabolic flux
• Production of glycoengineered proteins, specifically antibodies
• Enhanced control over protein glycosylation

Potential Applications: This technology can be applied in the pharmaceutical industry for the production of therapeutic antibodies with improved glycosylation patterns.

Problems Solved: This technology addresses the challenge of controlling and optimizing glycosylation patterns in protein production, specifically antibodies.

Benefits:

• Enhanced production of glycoengineered proteins
• Improved quality and consistency of therapeutic antibodies
• Potential for developing more effective biopharmaceuticals

Commercial Applications: The technology can be utilized in biopharmaceutical companies for the production of high-quality antibodies with optimized glycosylation patterns, leading to improved therapeutic outcomes and potentially expanding market opportunities.

Questions about Glycoengineered Proteins: 1. How does the lack of enzymes affecting sialic acid metabolic flux in host cells contribute to the production of glycoengineered proteins? 2. What are the potential implications of using glycoengineered proteins, such as antibodies, in the pharmaceutical industry?

Original Abstract Submitted

Compositions for producing glycoengineered proteins, e.g. antibodies, include host cells which lack the ability to produce enzymes that modulate sialic acid metabolic flux.